(VIANEWS) – Aurora Cannabis (NYSE: ACB) stock has witnessed an astounding drop over the last five trading sessions, falling by 16.67% from its previous closing price of EUR0.52 to EUR0.43 at 14:01 EST on Monday – following three straight sessions of losses.
Although Aurora Cannabis experienced a 72.47% drop from its 52-week high of EUR1.62, the NYSE managed a modest gain, rising 0.06% and closing at EUR0.45 last Friday.
Aurora Cannabis’s stock price plunge has sent shockwaves through investors and analysts, who are closely tracking its performance as well as any factors which may contribute to this drop.
About Aurora Cannabis
Aurora Cannabis Inc. is a Canadian company that manufactures, distributes, and sells medical and consumer cannabis products across Canada as well as internationally in Europe, Australia, South America and Israel. Aurora also distributes wholesale medical cannabis and hemp-derived CBD products. They cultivate their product line to include dried cannabis, oils capsules edibles extracts soft gels as well as recreational brands Aurora Drift San Rafael ’71 Daily Special Whistler as well as Reliva and KG7 CBD brands – and Aurora has its headquarters located near Leduc, Canada.
Yearly Analysis
Aurora Cannabis (ACB), a Canadian company, specializes in the production, distribution and sale of both medical cannabis products as well as consumer cannabis products. Their operations consist of four segments: Cannabis, Medical Cannabis, Wellness and Corporate.
Aurora Cannabis stock has recently fallen below its 52-week low of EUR0.43, signalling an undervalued position and providing investors with an opportunity to buy. Before making any definitive investment decisions, further investigation and analysis should be performed prior to making any definitive investments decisions.
Aurora Cannabis’s negative EBITDA of -27.79 may cause concern for investors, since EBITDA measures profitability and its presence suggests Aurora isn’t making enough profit to cover expenses. But investors should remember Aurora is still early in its growth journey and may invest heavily in research & development, marketing & expansion investments which may explain this temporary negative EBITDA situation.
Investors should carefully assess Aurora Cannabis’s financial performance, competitive position and growth prospects before making any investment decisions. Furthermore, investors must keep market trends and economic conditions in mind as these may have an effect on its performance.
Technical Analysis
Aurora Cannabis stock has been struggling to hold onto its value, with its current price significantly below both its 50-day and 200-day moving averages. Furthermore, today’s trading volume was just 10,948,652, representing significantly reduced trading activity compared to its typical average volume of 20,695,200.
The stock’s volatility has been decreasing recently, with its intraday variation average settling at negative 3.97% for the last week and month and positive 5.39% for quarter. Yet its amplitude of average volatility remains relatively constant – being between 4.35% for week, month, and quarter respectively.
Aurora Cannabis stock is currently considered overbought (>=80), signalling potential price correction in the near future. Investors should keep an eye on Aurora Cannabis’s volatility and trading activity to monitor any possible price movements in this stock.
Quarter Analysis
Based on this data, it appears that the company has experienced an impressive 49.9% annualized quarterly revenue growth since January 2015 – this indicates strong performance and strong expansion over the past twelve months.
Investors should keep a close eye on this trend as it could provide an indication of whether the company can achieve sustainable revenue growth over time. But keep in mind that revenue growth alone may not give a full picture of its financial health and performance.
Before making any investment decisions, investors should also carefully consider other factors, including a company’s profitability, debt levels, competitive landscape and overall market conditions. It is highly advised to conduct further research and analysis in order to establish whether this stock presents suitable investment opportunities.
Equity Analysis
Aurora Cannabis’s trailing twelve months earnings per share (EPS) figure of EUR-5.41 indicates it is currently operating at a loss, suggesting it may not generate sufficient revenues to cover expenses; as a result, investors should proceed with caution when considering investing in Aurora Cannabis.
Furthermore, the company’s negative return on equity of -102.67% for the twelve trailing months suggests that they are failing to generate profits for shareholders and is thus an alarming indication of financial instability within their operations.
Aurora Cannabis’ financial performance is cause for alarm, and investors must carefully examine its health before investing.
More news about Aurora Cannabis (ACB).
